





































JBH: contributed to the conception and design of the study, critical revision, reading, and approval of the manuscript.

JPK: contributed to the conception and design of the study, critical revision, reading, and approval of the manuscript.

MZD: contributed to the conception and design of the study, critical revision, reading, and approval of the manuscript.

## Figure Legends

**Figure 1** - *Number of immunosuppressed and non-immunosuppressed patients with sepsis at 60 hospitals in the Vizient database.* Blue = number of immunosuppressed patients with sepsis per hospital. Grey = number of non-immunosuppressed patients with sepsis per hospital.

**Figure 2** – *Adjusted odds of death due to a suppressed immune state for patients with sepsis at 60 hospitals in the Vizient database.* Grey open circle = odds of death due to a suppressed immune state at each hospital.\* Hospitals were grouped into quartiles according to the number of immunosuppressed patients with sepsis per year. Black solid circle = adjusted odds of death due to a suppressed immune state within each quartile using multilevel logistic regression.\*# Error bars represent 95% confidence intervals.

\*OR adjusted for each patient’s Vizient risk adjustment score, presence of hospital-acquired infection, and admission directly from another hospital or facility.

# OR adjusted for the following hospital characteristics: number of non-immunosuppressed patients with sepsis per year, transplant center, hospice unit, and geographic location.

**Figure 3** – *Observed number of deaths relative to expected number of deaths per hospital for immunosuppressed and non-immunosuppressed patients with sepsis.* Blue = immunosuppressed patients with sepsis. Grey = non-immunosuppressed patients with sepsis. Trends were determined using linear regression.

\*The expected number of deaths at each hospital was determined using a multilevel, multivariable logistic regression model with the following variables: each patient’s Vizient risk adjustment score, patient had a hospital-acquired infection, patient was admitted directly from an external hospital or facility, average number of non-immunosuppressed patients with sepsis per year at the hospital, hospital was a transplant center, hospital had a hospice unit, and geographic location of the hospital.

**Supplemental Figure 1** – *Flow diagram of hospital selection.*

**Supplemental Figure 2** – *Relationship between the number of immunosuppressed patients with sepsis and the percent of all patients with sepsis who were*

*immunosuppressed at each hospital per year.* Panel A includes all 62 hospitals. Panel B includes 60 hospitals with two outliers removed.

**Supplemental Figure 3** – *Odds of death for immunosuppressed and non-immunosuppressed patients with sepsis*, Hospitals were grouped into quartiles according to the number of immunosuppressed patients with sepsis per year. The reference category was non-immunosuppressed patients at hospitals in quartile 1. Blue = immunosuppressed patients with sepsis. Grey = non-immunosuppressed patients with sepsis. Error bars represent 95% confidence intervals.

## References

1. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. *Crit Care Med* 2013; 41: 1167-1174.
2. Vincent JL, Marshall JC, Namendys-Silva SA, Francois B, Martin-Loeches I, Lipman J, Reinhart K, Antonelli M, Pickkers P, Njimi H, Jimenez E, Sakr Y, investigators I. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. *Lancet Respir Med* 2014; 2: 380-386.
3. Esper AM, Martin GS. The impact of comorbid [corrected] conditions on critical illness. *Crit Care Med* 2011; 39: 2728-2735.
4. Wang HE, Shapiro NI, Griffin R, Safford MM, Judd S, Howard G. Chronic medical conditions and risk of sepsis. *PLoS One* 2012; 7: e48307.
5. Yende S, Alvarez K, Loehr L, Folsom AR, Newman AB, Weissfeld LA, Wunderink RG, Kritchevsky SB, Mukamal KJ, London SJ, Harris TB, Bauer DC, Angus DC, Atherosclerosis Risk in Communities S, Cardiovascular Health S, Health A, Body Composition S. Epidemiology and long-term clinical and biologic risk factors for pneumonia in community-dwelling older Americans: analysis of three cohorts. *Chest* 2013; 144: 1008-1017.
6. Yende S, Iwashyna TJ, Angus DC. Interplay between sepsis and chronic health. *Trends Mol Med* 2014; 20: 234-238.
7. Poutsiaka DD, Davidson LE, Kahn KL, Bates DW, Snyderman DR, Hibberd PL. Risk factors for death after sepsis in patients immunosuppressed before the onset of sepsis. *Scand J Infect Dis* 2009; 41: 469-479.
8. Tolsma V, Schwebel C, Azoulay E, Darmon M, Souweine B, Vesin A, Goldgran-Toledano D, Lugosi M, Jamali S, Cheval C, Adrie C, Kallel H, Descorps-Declere A, Garrouste-Orgeas M, Bouadma L, Timsit JF. Sepsis severe or septic shock: outcome according to immune status and immunodeficiency profile. *Chest* 2014; 146: 1205-1213.
9. Walkey AJ, Wiener RS. Hospital case volume and outcomes among patients hospitalized with severe sepsis. *Am J Respir Crit Care Med* 2014; 189: 548-555.
10. Gu WJ, Wu XD, Zhou Q, Zhang J, Wang F, Ma ZL, Gu XP. Relationship between Annualized Case Volume and Mortality in Sepsis: A Dose-Response Meta-analysis. *Anesthesiology* 2016.

11. Gaieski DF, Edwards JM, Kallan MJ, Mikkelsen ME, Goyal M, Carr BG. The relationship between hospital volume and mortality in severe sepsis. *Am J Respir Crit Care Med* 2014; 190: 665-674.
12. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001; 29: 1303-1310.
13. Greenberg JA, Hohmann SF, Hall JB, Kress JP, David MZ. Validation of a Method to Identify Immunocompromised Patients with Severe Sepsis in Administrative Databases. *Ann Am Thorac Soc* 2016; 13: 253-258.
14. Shaw JJ, Santry HP. Who Gets Early Tracheostomy?: Evidence of Unequal Treatment at 185 Academic Medical Centers. *Chest* 2015; 148: 1242-1250.
15. Page DB, Donnelly JP, Wang HE. Community-, Healthcare-, and Hospital-Acquired Severe Sepsis Hospitalizations in the University HealthSystem Consortium. *Crit Care Med* 2015; 43: 1945-1951.
16. Jamme M, Daviaud F, Charpentier J, Marin N, Thy M, Hourmant Y, Mira JP, Pene F. Time Course of Septic Shock in Immunocompromised and Nonimmunocompromised Patients. *Crit Care Med* 2017.
17. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinhan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Crit Care Med* 2017; 45: 486-552.
18. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, Guest CB, Mazer CD, Mehta S, Stewart TE, Kudlow P, Cook D, Slutsky AS, Cheung AM, Canadian Critical Care Trials G. Functional disability 5 years after acute respiratory distress syndrome. *The New England journal of medicine* 2011; 364: 1293-1304.
19. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. *Jama* 2010; 304: 1787-1794.
20. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I, Infectious Diseases Society of A. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014; 58: 309-318.